Description
Approved accessible “bevacizumab-adcd injection”
Bevacizumab, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy.[20][18] For age-related macular degeneration it is given by injection into the eye (intravitreal). Bevacizumab was approved for medical use in the United States in 2004. It is on the World Health Organization’s List of Essential Medicines. It is listed for its use in treating eye disease.
Vegzelma (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab), is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1) and kinase insert domain receptor (VEGFR-2) on the surface of endothelial cells.
Avastin is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, platinum-resistant recurrent epithelial ovarian and fallopian tube or primary peritoneal cancer.
How can 1 go about obtaining bevacizumab-adcd injection?
If bevacizumab-adcd injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
- VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022
- AVASTIN (bevacizumab) Solution for intravenous infusion Initial U.S. Approval: 2004
References
- Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC
- FDA Approves Vegzelma, a Biosimilar to Bevacizumab, for Six Types of Cancer